Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.71 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.71 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.71 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL583138 | 0.93 | OR51E2 (0.71) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL16600 | 0.93 | GLRA1 (0.71) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL7078758 | 0.93 | OR51E2 (0.71) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL25331377 | 0.90 | GLRA1 (0.67) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL25333179 | 0.90 | OR51E2 (0.67) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL25362123 | 0.90 | OR51E2 (0.67) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL6237269 | 0.86 | OR51E2 (0.71) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL6237177 | 0.86 | OR51E2 (0.71) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL978831 | 0.86 | GLRA1 (0.71) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL978830 | 0.86 | GLRA1 (0.71) | OR51E2GLRA1SLC6A9GABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110268235-A1 | BORON-10 ENHANCED THERMAL ENERGY | GURIN MICHAEL | 2011-11-03 | — | — | US | claimed |
| WO-2005011737-A2 | PHARMACEUTICAL COMBINATIONS AND FORMULATIONS WITH IMPROVED STABILITY | CIPLA LIMITED (IN) | 2005-02-10 | — | — | WO | claimed |
| EP-1006997-B1 | EFFERVESCENT MICROSPHERES AND METHOD FOR MAKING THEM | PF MEDICAMENT (FR) | 2003-07-02 | — | — | EP | claimed |
| US-6210711-B1 | MULTILAYER MICROSPHERES CONTAINING AN ACID SUBSTANCE, A BASIC SUBSTANCE, AND A WATER-SOLUBLE ISOLATING AGENT WHICH, WHEN IT DISSOLVES IN WATER, AFTER ALMOST INSTANT EFFERVESCENCE, BRINGS ABOUT A HOMOGENEOUS DISPERSION OF ACTIVE PRINCIPAL(S) | PIERRE FABRE MEDICAMENT (FR) | 2001-04-03 | — | — | US | claimed |
| EP-1006997-A1 | EFFERVESCENT MICROSPHERES AND METHOD FOR MAKING THEM | PIERRE FABRE MEDICAMENT (FR) | 2000-06-14 | — | — | EP | claimed |
| WO-1998031342-A1 | EFFERVESCENT MICROSPHERES AND METHOD FOR MAKING THEM | PIERRE FABRE MEDICAMENT (FR) | 1998-07-23 | — | — | WO | claimed |
| US-9951949-B1 | Ultra-high energy density and emissivity for energy conversion | GURIN MICHAEL H (US) | 2018-04-24 | — | — | US | disclosed |
| US-20110268235-A1 | BORON-10 ENHANCED THERMAL ENERGY | GURIN MICHAEL | 2011-11-03 | — | — | US | disclosed |
| US-20070218131-A1 | EFFERVESCENT FORMULATIONS COMPRISING DESMOPRESSIN | ARDANA BIOSCIENCE LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| CN-1953738-A | Effervescent agent containing desmopressin | ARDANA BIOSCIENCE LTD (GB) | 2007-04-25 | — | — | CN | disclosed |
| US-20070087054-A1 | EFFERVESCENT FORMULATIONS OF OXYTOCIN | ARDANA BIOSCIENCE LIMITED (GB) | 2007-04-19 | — | — | US | disclosed |
| US-20070071818-A1 | EFFERVESCENT FORMULATIONS COMPRISING APOMORPHINE | ARDANA BIOSCIENCE LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1725220-A1 | EFFERVESCENT FORMULATIONS COMPRISING DESMOPRESSIN | Ardana Bioscience Limited (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005011737-A2 | PHARMACEUTICAL COMBINATIONS AND FORMULATIONS WITH IMPROVED STABILITY | CIPLA LIMITED (IN) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004026279-A1 | EFFERVESCENT FORMULATIONS OF OXYTOCIN | ARDANA BIOSCIENCE LIMITED (GB) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026309-A1 | EFFERVESCENT FORMULATIONS COMPRISING APOMORPHINE | ARDANA BIOSCIENCE LIMITED (GB) | 2004-04-01 | — | — | WO | disclosed |
| EP-1006997-B1 | EFFERVESCENT MICROSPHERES AND METHOD FOR MAKING THEM | PF MEDICAMENT (FR) | 2003-07-02 | — | — | EP | disclosed |
| US-6210711-B1 | MULTILAYER MICROSPHERES CONTAINING AN ACID SUBSTANCE, A BASIC SUBSTANCE, AND A WATER-SOLUBLE ISOLATING AGENT WHICH, WHEN IT DISSOLVES IN WATER, AFTER ALMOST INSTANT EFFERVESCENCE, BRINGS ABOUT A HOMOGENEOUS DISPERSION OF ACTIVE PRINCIPAL(S) | PIERRE FABRE MEDICAMENT (FR) | 2001-04-03 | — | — | US | disclosed |
| EP-1006997-A1 | EFFERVESCENT MICROSPHERES AND METHOD FOR MAKING THEM | PIERRE FABRE MEDICAMENT (FR) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998031342-A1 | EFFERVESCENT MICROSPHERES AND METHOD FOR MAKING THEM | PIERRE FABRE MEDICAMENT (FR) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218131-A1 | EFFERVESCENT FORMULATIONS COMPRISING DESMOPRESSIN | AVPR2, AVPR1A, AVPR1B | OR51E2 1120/4885GLRA1 1689/4885SLC6A9 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.